Skip to NavigationSkip to content

BMS unveils strong five-year efficacy data for Opdivo in lung cancer

Published on 11/09/19 at 10:06am

Bristol-Myers Squibb has unveiled pooled five-year efficacy and safety results for its blockbuster immunotherapy Opdivo (nivolumab) drawn from two Phase 3 studies in the treatment of previously treated advanced non-small cell lung cancer (NSCLC).

BMS’ immunotherapy demonstrated overall survival rates of 13.4% across all patient subgroups after five years of treatment, compared to just 2.6% with docetaxel. Furthermore, 32.2% of patients who achieved an objective response to Opdivo continued to respond after five years of treatment, whereas no patients who achieved an objective response with docetaxel still saw a response after the same period.

Additionally, median duration of response in patients treated with Opdivo was 19.9 months, compared just 5.6 months with docetaxel, while the therapy’s safety profile was also found to be consistent with previous data in second-line NSCLC.

“Since the U.S. Food and Drug Administration approval in second-line non-small cell lung cancer in 2015, Opdivo has become an important treatment option for this population of patients, who historically faced five-year survival rates of less than 5% when treated with standard chemotherapy,” remarked Dr Sabine Maier, Development Lead, Thoracic Cancers, at Bristol-Myers Squibb. “The long-term survival outcomes from these two studies in a large patient population add to the body of evidence supporting the durability of Opdivo-based regimens, which has now been demonstrated across multiple tumour types and lines of therapy.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches